Difficulty: Medium
Average Score: 78%
Practice
Phenobarbitone reduces the incidence of severe hyperbilirubinaemia in neonates because
Correct answer
C
Rationale
In the context of CNS pharmacology and neonatal care, understanding the mechanism of action of Phenobarbitone in reducing severe hyperbilirubinaemia in neonates is crucial. The correct answer is C) It stimulates hepatic glucuronyl transferase. This is because Phenobarbitone induces the activity of hepatic glucuronyl transferase, an enzyme responsible for conjugating bilirubin into a water-soluble form that can be excreted from the body. By increasing the activity of this enzyme, Phenobarbitone helps in reducing the levels of unconjugated bilirubin, which is implicated in causing severe hyperbilirubinaemia in neonates.
Option A) It prevents the synthesis of bilirubin is incorrect because Phenobarbitone does not directly inhibit the synthesis of bilirubin. Instead, it acts on the metabolism of bilirubin.
Option B) It conjugates with the bilirubin is incorrect because Phenobarbitone does not conjugate with bilirubin itself. It induces the enzyme responsible for the conjugation process.
Option D) None of the above mechanisms is incorrect because Phenobarbitone does have a specific mechanism of action in reducing hyperbilirubinaemia, which is through the induction of hepatic glucuronyl transferase activity.
Understanding the pharmacological actions of drugs like Phenobarbitone in neonatal care is essential for healthcare providers to make informed decisions regarding the management of conditions like hyperbilirubinaemia. By grasping the specific mechanisms of action, healthcare professionals can optimize drug therapy and improve patient outcomes in neonatal care settings.
Option A) It prevents the synthesis of bilirubin is incorrect because Phenobarbitone does not directly inhibit the synthesis of bilirubin. Instead, it acts on the metabolism of bilirubin.
Option B) It conjugates with the bilirubin is incorrect because Phenobarbitone does not conjugate with bilirubin itself. It induces the enzyme responsible for the conjugation process.
Option D) None of the above mechanisms is incorrect because Phenobarbitone does have a specific mechanism of action in reducing hyperbilirubinaemia, which is through the induction of hepatic glucuronyl transferase activity.
Understanding the pharmacological actions of drugs like Phenobarbitone in neonatal care is essential for healthcare providers to make informed decisions regarding the management of conditions like hyperbilirubinaemia. By grasping the specific mechanisms of action, healthcare professionals can optimize drug therapy and improve patient outcomes in neonatal care settings.